Download
Simbrich-et-al_2019_Drug use patterns and severe adverse events of disease-modifying drugs in patients with multiple sclerosis_A cohort study based on German claims data.pdf 306,05KB
WeightNameValue
1000 Titel
  • Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: a cohort study based on German claims data
1000 Autor/in
  1. Simbrich, Alexandra |
  2. Thibaut, Jasmine |
  3. Khil, Laura |
  4. Berger, Klaus |
  5. Riedel, Oliver |
  6. Schmedt, Niklas |
1000 Erscheinungsjahr 2019
1000 LeibnizOpen
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2019-05-28
1000 Erschienen in
1000 Quellenangabe
  • 15:1439-1457
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2019
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.2147/NDT.S200930 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549763/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • PURPOSE: To describe drug-use patterns in patients with multiple sclerosis (MS) using disease-modifying drugs (DMDs) and to estimate the incidence of severe adverse events (SAEs) of treatment. METHODS: We conducted a cohort study within the German Pharmacoepidemiological Research Database between January 1, 2006 and December 31, 2013. MS patients on DMDs were described in terms of clinical characteristics and drug-use patterns. Next, we assessed the incidence of AEs in new users of fingolimod, natalizumab, glatiramer acetate, and IFNβ1a. RESULTS: Among approximately 11 million insured members of German Statutory Health Insurance, the DMD-user cohort comprised 15,377 patients with MS, with a mean age of 39.6 years and 68% females. Nearly half of all DMD users had a diagnosis of depression, with prevalence ranging from 40.1% for IFNβ1a to 62.3% for immunoglobulins. The overall rate of MS relapses per patient and year was 0.34 (95% CI 0.33–0.34). During an average follow-up of 1,650 days, the majority (42.4%) of MS patients were adherent to DMD treatment (“continuous single users”), followed by patients interrupting treatment (39.5%, “interrupters”). Switch of DMD treatment (11.9%) was less frequent, and only 5.6% discontinued treatment. Treatment discontinuation was most common in users of natalizumab (7.5%) and IFNβ1b (7.0%). The most frequent SAE was hospitalization for depression, followed by any infectious disease and any malignancy. The incidence rate of all adverse events did not significantly differ across different DMDs. CONCLUSION: Treatment discontinuation with DMDs and treatment switch were rare. Causes of rather frequent DMD-treatment interruption have to be evaluated in further studies based on primary data collection. Active safety monitoring of new DMDs based on claims data requires large data sets to detect rare AEs and availability of up-to-date data.
1000 Sacherschließung
lokal Adverse events
lokal Multiple sclerosis
lokal Disease-modifying drugs
lokal Claims data
lokal Drug-use patterns
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0001-8689-6634|https://orcid.org/0000-0001-9124-8404|https://frl.publisso.de/adhoc/uri/S2hpbCwgTGF1cmE=|https://frl.publisso.de/adhoc/uri/QmVyZ2VyLCBLbGF1cw==|https://orcid.org/0000-0002-1721-502X|https://frl.publisso.de/adhoc/uri/U2NobWVkdCwgTmlrbGFz
1000 Label
1000 Förderer
  1. Bundesministerium für Bildung und Forschung |
  2. Biogen |
1000 Fördernummer
  1. 01GI0907
  2. -
1000 Förderprogramm
  1. Competence Network of Multiple Sclerosis (“Kompetenznetz Multiple Sklerose”, KKNMS)
  2. -
1000 Dateien
  1. Drug use patterns and severe adverse events of disease-modifying drugs in patients with multiple sclerosis_A cohort study based on German claims data
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Bundesministerium für Bildung und Forschung |
    1000 Förderprogramm Competence Network of Multiple Sclerosis (“Kompetenznetz Multiple Sklerose”, KKNMS)
    1000 Fördernummer 01GI0907
  2. 1000 joinedFunding-child
    1000 Förderer Biogen |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6415323.rdf
1000 Erstellt am 2019-07-22T12:16:39.116+0200
1000 Erstellt von 266
1000 beschreibt frl:6415323
1000 Bearbeitet von 122
1000 Zuletzt bearbeitet Mon Jul 29 09:27:24 CEST 2019
1000 Objekt bearb. Mon Jul 29 09:27:13 CEST 2019
1000 Vgl. frl:6415323
1000 Oai Id
  1. oai:frl.publisso.de:frl:6415323 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source